Kiniksa Pharmaceuticals, Ltd. (NASDAQ: KNSA) reported Q2 EPS of $0.23, $0.04 better than the analyst estimate of $0.19. Revenue for the quarter came in at $156.79 million versus the consensus estimate of $145.28 million.

GUIDANCE:

Kiniksa Pharmaceuticals, Ltd. sees FY2025 revenue of $625-640 million, versus the consensus of $604 million.

For earnings history and earnings-related data on Kiniksa Pharmaceuticals, Ltd. (KNSA) click here.